Rationale: Adenosine (ADO) signaling is altered in both asthma and chronic obstructive pulmonary disease and the A 2B adenosine receptor (A 2B -R) may drive pulmonary inflammation.
Introduction
Altered adenosine (ADO) signaling has been associated with both asthma and chronic obstructive pulmonary disease (COPD) (1, 2) . For example, inhaled ADO causes bronchoconstriction in asthmatics despite having little effects on normal subjects (3) and adenosine receptor (ADO-R) expression is altered in COPD (4) . ADO is formed in airway lumens as a breakdown product of ATP (5, 6) and can signal through specific ADO receptors before being broken down by adenosine deaminase (ADA) (7, 8) . A 1 and A 3 receptors signal through G i/o proteins to inhibit adenylyl cyclase, and in some cases, to activate Ca 2+ , while A 2A and A 2B receptors signal through G s to activate adenylyl cyclase and raise cAMP (7) . ADO can stimulate A 2B receptors (A 2B -R) to induce cytokine release from mast cells, smooth muscle and epithelia (9) . Further, adenosine deaminase-null mice, which exhibit raised airway ADO levels, displayed elevated IL-13 levels and chronic airway remodeling which can be reversed by specific A 2B -R blockade (10, 11) . Thus, inhibition of A 2B -R has been proposed as a potential therapy for treating chronic airway diseases (12, 13) .
Despite data showing that ADO can be pro-inflammatory, ADO is also required for maintenance of the mucus component of the innate lung defense system (14) . Airway surface liquid (ASL) height must be kept at ≥ 7 µm to keep mucus away from the epithelial surface to allow cilia to beat and maintain efficient mucus transport. This complex process is in part mediated by ADO, which activates CFTR-mediated Cl -secretion in human nasal epithelia in vivo and directly regulates both CFTR Cl -channels and the epithelial Na + channel (ENaC) in cultured airways (15) (16) (17) . Removal of ADO, inhibition of ADO-R or a lack of CFTR (i.e. in CF airway epithelia) all result in a failure to regulate ASL height to 7 µm and result in a decrease in ASL height to CF-like levels (i.e. ~3 µm) (5, 18) . This ASL depletion causes mucus stasis and is predicted to cause mucus plugging (19) . Thus, there appears to be a requirement for ADO to be present in the ASL in order to activate CFTR and sufficiently hydrate the mucus layer. The relatively high levels of ADO required to activate CFTR (≥ 1 µM) suggest that CFTR is regulated by the A 2B -R. However, ASL ADO is typically sub µM, as measured by lavage (20) , which has lead investigators to suggest that the A 2B -R, which has an EC 50 of ~2 µM, is not physiologically active (12) .
Since inhibition of A 2B -R has potential benefits with regard to reducing airway inflammation, it has become an attractive therapeutic target for the treatment of chronic lung disease. However, if A 2B -R also regulates CFTR, then inhibition of this receptor may also induce ASL volume depletion. Thus, we set out to determine which ADO-R are expressed in the superficial airway epithelium and whether specific A 2B -R blockade could inhibit ASL volume homeostasis.
Methods and Materials
Please see the online supplement for more detailed methods including the lists of primers and solutions/chemicals used.
Laser capture microscopy, qPCR and primer sequences
Normal human bronchi obtained immediately after lung transplant surgery were snap frozen in OCT (Tissue-Tek), sectioned at 8 µm and the sections placed on Leica PEN slides.
Ciliated cells were identified by light microscopy and laser captured onto HS LCM caps (Arcturus) and RNA was isolated using PicoPure RNA Isolation Kit (Arcturus). RNA was converted to cDNA and measured by LightCycler as described previously (21) .
In vivo nasal potential differences (PDs).
The study protocol was approved by the UNC Committee on the Protection of Rights of Human Subjects. Mean age was 27 ± 3 years (n=6). PD was measured between a subcutaneous reference electrode and an exploring electrode placed against the inferior turbinate as previously described (22) . For each subject, the PD was recorded in both nostrils and an average taken.
Measurement of in vivo nasal ASL ADO.
Lavage of 5 ml 37°C saline was instilled into each naris over a period of 30 s in a 37°C humidified room and retrieved over 15 s and placed on ice. Adenosine derivatization was performed as previously described (23) .
Isolation and culture of human bronchial epithelia
Human excess donor tissue was obtained at the time of lung transplantation from portions of main stem or lumbar bronchi under a protocol approved by the UNC medical school IRB and cells were harvested by enzymatic digestion seeded directly as primary cultures on 12 mm
Transwell Clear or Snapwell inserts (Costar) in modified BEGM media under air-liquid interface conditions, and studied when fully differentiated (2-5 weeks) as described previously (24) .
Ussing Chamber measurements of transepithelial potential difference
HBECs were mounted in Ussing chambers as previously described (25) .
Confocal microscopy measurements of ASL height
ASL was stained with either FITC or Texas red-dextran and measured using a Lecia SP5
inverted confocal microscope with a 63 x glycerol immersion lens as previously described (21) .
Intracellular Ca 2+ and cAMP measurements
HBECs were loaded with free Fura-2 by incubation in 2.5 µM Fura-2/AM at 37°C for 45 min. Cells were then washed and the fluorescence intensity ratio (excitation 340/380, emission >450 nm) was collected as previously described (18) .
cAMP was measured as previously described (23) by enzyme immunoassay (SigmaAldrich). Cellular cAMP was normalized to protein as determined by the BCA method (Pierce Biotechnology Inc.).
Statistics
All data are presented as the mean ± SE for n experiments. For in vitro experiments, cultures derived from three or more patients were used. Differences between means were tested for statistical significance using paired or unpaired t tests or their non parametric equivalent as appropriate to the experiment. From such comparisons, differences yielding P ≤ 0.05 were judged to be significant.
Results

In vivo expression of adenosine receptors
CFTR is present in ciliated cells in the surface epithelia (26) and functionally, these cells are thought to be a major source of transepithelial Cl -secretion (27) . To see which ADO-R are expressed in the superficial epithelium in vivo, we performed laser capture to remove groups of ciliated cells from freshly frozen sections of normal human bronchial epithelia. Fig. 1A shows a typical region obtained by laser capture. mRNA samples from ciliated cells were then reversed transcribed to make cDNA for real time PCR analysis. A 1 receptors were not detected in ciliated cells from any of the donors (Fig. 1B) . The A 2B receptor was the most highly expressed, with A 2A and A 3 receptors being ~3-5 fold less abundant (Fig. 1B) .
Adenosine receptor blockade inhibits CFTR activation in vivo
Using the nasal PD technique, Clancy and colleagues demonstrated that ADO activates CFTR mediated Cl -secretion in vivo (15) . To test whether ADO-R antagonism would prevent activation of CFTR mediated Cl -secretion in vivo, we measured the change in nasal potential difference in six normal subjects after ADO-addition. Since we cannot add specific A 2B -R antagonists in vivo, we added the non-specific ADO-R antagonist caffeine at 30 µM which is close to the IC 50 for the A2B-R but is predicted to be too low to affect phosphodiesterase activity (28, 29) .
After amiloride addition to inhibit ENaC, we added a a low Cl -mucosal solution with 10
µM ADO to generate a maximal gradient for Cl -secretion and stimulate A2B-R. This caused an ~20 mV hyperpolarization of the PD, which is indicative of activation of significant Cl -secretion ( Fig. 2A ). In the same subjects, addition of 30 µM caffeine to the low Cl -Ringer reduced this response by 75%, suggesting that ADO-R blockade attenuates CFTR-mediated Cl -secretion ( Fig. 2A ).
Isoproterenol (ISO) stimulates CFTR mediated Cl -secretion via β2 adrenergic receptors and in our hands, stimulated Cl -secretion to a similar degree to ADO (Fig. 2B ) (27) . However, the ISO response was not altered by caffeine, suggesting that caffeine acted specifically to inhibit A2B-R (Fig. 2B ).
To test whether in vivo nasal ADO levels are sufficient to activate CFTR-mediated Cl -secretion, we next collected nasal ASL by lavage. During tidal breathing, nasal ASL ADO was 740 ± 78 nM (n = 8 subjects), suggesting that A 2B -R is ~25% active in nasal epithelia in vivo.
The A 2B -R is the most highly expressed ADO-R in airway epithelial cultures.
We have previously demonstrated that ADO-addition can acutely stimulate ASL secretion in normal human bronchial epithelial cultures (HBECs) (21) . To identify which ADO-R were expressed in our HBEC system, we first performed a PCR analysis on RNA isolated from HBECs, which represent a ciliated cell-rich population. Similar to bronchial ciliated cells in vivo ( Fig. 1 ) A1 receptors were not expressed in HBECs (Fig. 3A) . However, unlike ciliated cells in vivo or positive controls from whole lung and brain, A 3 ADO receptors could not be detected in HBECs from 3 separate donors (two male, one female) and A 2A receptors were barely detectable ( Fig. 3A) . In contrast, A 2B receptors appeared to be consistently expressed in cultures from all three donors (Fig. 3A) .
The PCR study indicated that the A 2B -R was the most highly expressed ADO-R in HBECs. A 2B -R is the least sensitive of the ADO-R to ADO, with an EC 50 of ~ 2 µM (7). To determine the EC 50 for ADO activation of Cl -secretion in our culture system, we measured the transepithelial potential difference (V t ) under open circuit conditions in airway cultures mounted in Ussing chambers in the presence of mucosal amilorde and a mucosal low Cl -solution. Under these conditions, ADO produced a dose-dependent increase in PD with an EC 50 of 1.6 ± 0.09 µM, which is consistent with activation of A 2B -R (Fig. 3B ).
To confirm that the A 2B receptor underlay the increase in ASL height in response to ADO, we next measured ASL height by XZ confocal microscopy before, and 10 min after the addition of ~300 µM ADO or its analogues suspended as a dry powders suspended in perfluorocarbon, so as not to disturb the ASL by addition of a liquid vehicle (Fig. 3C) . N.B., for this study, all cultures were pretreated with aprotinin to inhibit ENaC and hyperpolarize the apical membrane to provide a favourable gradient for Cl -secretion (21) . Consistent with A 2B -R being the most highly expressed ADO-R in the HBECs, we observed full stimulation of ASL secretion with NECA and partial stimulation with CGS21680. In contrast, the A 1 -R & A 3 -R agonists IB-MECA and R-PIA failed to induce ASL secretion (Fig. 3C) .
Pretreatment of the mucosal surface with the non-specific ADO-R inhibitor caffeine, the and MRS1191 respectively) (31-33) had no effect on secretion (Fig. 3D ).
To confirm that inhibition of CFTR attenuates ASL volume secretion, we pretreated
HBECs with the CFTR inhibitor glibenclamide (10 µM) (34) , which directly inhibits CFTR and ASL secretion in response to ADO (Fig. 3D ). In contrast, DIDS (100 µM), which inhibits the Ca 2+ -activated Cl -channel (35) had no effect on ADO-mediated ASL secretion (Fig. 3D ).
The effect of ADO on HBEC cell signaling
Stimulation of A 1 -R, A 2B -R and A 3 -R has previously been shown to increase Ca 2+ i via linkage of these receptors to G q (7, 36) . However, 100 µM ADO had no effect on intracellular Ca 2+ , suggesting that ADO did not stimulate G q in bronchial epithelia (Fig. 4A) . To confirm that our system was operating normally, we also exposed the HBECs to ATP, which caused an ~3
fold increase in the Fura 2 emission ratio (Fig. 4A) . In contrast, stimulation of HBECs with 30
µM ADO caused a robust increase in cAMP that was attenuated by alloxazine addition (Fig. 4B) ,
suggesting that HBEC A 2B -R are coupled to G s to raise intracellular cAMP.
ADO acts as a sensor to mediate ASL volume homeostasis via A 2B receptors.
Normal airway epithelia spontaneously regulate ASL height to ≥7 µm, although the mechanism whereby ASL volume status is signaled to the epithelia is not fully understood (37).
We have hypothesized that the concentration or dilution of molecules in the ASL such as ADO is crucial in setting the ASL to appropriate heights (37) . To test whether ADO acts as a concentration-dependent signal to regulate ASL volume, we pretreated cultures with ADA to remove any exogenous ADO. Since ADO is rapidly hydrolyzed on airway surfaces, we dosed cultures with a test "ASL" containing different concentrations of NECA, a poorly hydrolyzed analogue of ADO. To confirm that NECA was not hydrolyzed by ADA, we added 1 unit/ml adenosine deaminase and 1 µM NECA to 1 ml Ringer solution for 1 h, and then measured
[NECA] by HPLC, following etheno-derivatization of NECA (see METHODS). After 1 h, the NECA concentration was unchanged, confirming that it is resistant to hydrolysis by ADA.
HBECs exposed to ADA with 10 nM NECA were unable to regulate ASL height (5A,B). In contrast, addition of 100 nM NECA to the test ASL resulted in a constant ASL height over 8 h (i.e. neither absorption nor secretion), while 1 µM NECA addition caused an increase in ASL height over 8 h that was almost identical to the control cultures which did not have ADA/NECA and were unable to autoregulate ASL height (Fig. 5A,B ).
To test that there was an absolute requirement for A 2B -R to regulate this system, we added 30 µl PBS to HBEC surfaces containing fluorescent dextran and ADO-R antagonists. We then aspirated excess ASL to preset ASL height at ~5 µm and measured ASL height by XZ confocal microscopy 2 and 8 h after exposure to a panel of ADO-R antagonists. In control cultures, ASL height was readjusted to ~7 µm within 2 h, a height that was maintained for a further 6 h (Fig. 6 ). Cultures pretreated with the A 2 -R antagonist alloxazine or the A 2B -R specific antagonist ATL801 were unable to regulate ASL height, consistent with a lack of Cl -secretion in the absence of ADO (Fig. 6A, B) . In contrast, cultures exposed to the A1, A2 A and A3 receptor antagonists DPCPX, ZM241385 and MRS1191 (all at 10 µM) maintained ASL height regulation over 8 h that was indistinguishable from control cultures (Fig. 6C, D) .
Discussion
Precise regulation of ASL height (volume) is crucial for maintaining mucus clearance and for keeping the lungs free from bacterial and viral infections. We have previously found that ADO must be present in the ASL for normal ASL homeostasis and mucus transport (37 We found that the A 2B -R was the most highly expressed ADO-R in freshly obtained human bronchial epithelium and ADO addition activated CFTR-mediated Cl -secretion in vivo ( Figs. 1 and 2 ). ADO measured by lavage in vivo was ~740 nM and since the EC 50 for the A 2B -R is ~1-2 µM, this amount of endogenous ADO would be predicted to activate the A 2B -R by ~25%
in vivo. Pretreatment with caffeine attenuated this activation (Fig. 2) . Caffeine is a non-specific ADO-R antagonist and we cannot exclude the possibility that this activation was mediated by A 2A -R. However, A 2A -R is thought to be serosally located in the airway epithelia and may not have been activated during our nasal PD experiments (38) . Caffeine can also act as a phosphodiesterase inhibitor, which could raise cAMP and confound our results. However, at low µM concentrations caffeine does not alter CFTR activity, suggesting that this concentration is insufficient to alter phosphodiesterase activity and that the observed effects were purely due to the inhibitory effects of caffeine on ADO-R (28).
Both A1-R and A3-R have been detected in airway epithelia. For example, McCoy et al.
showed that inhibition of A1-R increased cAMP and stimulated a Cl -conductance in immortalized normal and CF cell lines, as well as in CF nasal polyps (39 (38) .
The A 2B -R has been implicated in regulation of CFTR and Cl -secretion by several groups both using cell lines such as CALU3s (23, 42) and in primary nasal cultures (43) . Based on our PCR data and our inhibitor studies, this also appears to be the case in bronchial epithelia. We found no effect of ZM241385 on ASL height (Figs. 3 & 6) , unlike ATL801 exposure which consistently inhibited ASL volume homeostasis (Fig. 3 & 6) . However, Linden et al. have
reported that ZM241385 also blocks A 2B -R in the micromolar range (44) , suggesting that this compound may have tissue-specific activities.
We have previously reported that ASL ADO concentrations are ~100 nM in our HBECs (5, 18) . This is lower than what has previously been measured by bronchoalveolar lavage (20) and this difference may reflect the absence of airflow-induced shear stress which can drive ATP release and ADO formation. Also, since macrophages are absent from our culture system, their contribution to ASL ADO is not accounted for. Further, we have not been able to directly measure ASL ADO at the epithelial surface, and our estimates are based on measurements of ADO in bulk solution (i.e. ~50 µl of PBS added to culture surfaces rather than true "thin film" conditions). ATP has previously been shown to be 2-3 log units higher at the cell surface than in lavage using luciferase attached to the cell surface and this phenomenon may occur with other molecules such as ADO (45) .
To gain an appreciation of the ADO concentration required to regulate ASL volume, we replaced ASL with test solutions containing adenosine deaminase (ADA) to remove any endogenous ADO in the presence of the non-hydrolysable ADO analogue NECA. ADA addition with 10 -8 M NECA caused a rapid (< 2 h) depletion of ASL volume to minimal levels while addition of 10 -7 M NECA with ADA caused neither absorption nor secretion, and 10 -6 NECA with ADA caused ASL height to increase in a similar fashion to cultures exposed to PBS alone.
NECA is ~10 times more potent than ADO for the A 2B -R, so these data suggest that if 0.1 -1 µΜ NECA is required to regulate ASL volume, then the cell surface ADO concentration must be ~1
-10 µM in native ASL to activate A 2B -R, stimulate CFTR and maintain ASL volume appropriately. Based on our dose response to ADO for Cl -secretion (Fig. 3B) , this concentration of ADO would be sufficient to activate the A 2B -R and regulate ASL height and is consistent with A2B-R inhibition causing a collapse of ASL volume (Fig. 6A, B) .
Based on data showing that ADO is raised in chronic lung diseases (12, 13) and that pharmacological inhibition of A 2B -R in mice reduces inflammation (11, 46) , the blockade of A 2B -R has been proposed as a treatment for inflammation in chronic lung disease. However, while there is undeniably a link between ADO and inflammation, recent studies using A 2B -R knockout mice have suggested that A2B-R is anti-inflammatory (47, 48) . However, CFTR expression is not required in murine airways, as evidenced by the lack of phenotype of CF mice (49) and the inhibition of A 2B -R and subsequent CFTR disregulation would not be expected to have any measurable effect on murine airway phenotype. We and others have proposed that the A 2B -R regulates CFTR in human airways (15, 18, 23, 50) , suggesting that A 2B -R inhibition may dangerously impinge upon CFTR regulation in vivo. Thus, based on our emerging understanding of A 2B -R-CFTR signaling, we propose that chronic addition of A 2B -R antagonists to non-CF subjects could inhibit CFTR-mediated ASL volume homeostasis, accentuating mucus accumulation in COPD or asthma. In contrast, A 2B -R antagonists may be beneficial in CF lung disease: ENaC is positively regulated by cAMP in the absence of CFTR (19) , so A 2B -R inhibition may be therapeutically useful CF in damping down ENaC-led hyperabsorption in addition to any inhibitory effects on A 2B -R-induced inflammation.
In conclusion, we find that the A 2B -R is the only ADO receptor expressed in primary bronchial epithelial cultures and despite its insensitivity to ADO relative to other ADO-Rs, chronic activation of this receptor is required for ASL volume homeostasis. It is likely that the cell surface ADO concentration is greater than can be measured by lavage and that airway epithelia sense the concentration of ADO to regulate CFTR activity, and that this action occurs in parallel with regulation of ENaC, by CFTR and by extracellular proteases and protease inhibitors (21) . Factors that change ADO in the airways such as shear stress (14) 
